In their phase 2 clinical trial, Daly and colleagues assess the use of adjunctive intranasal esketamine in the management of treatment-resistant depression. Participants (n=67) were initially randomly allocated to placebo or esketamine (28 mg, 56 mg, or 84 mg) twice a week. In the second week of the study, placebo participants with moderate-to-severe symptoms were randomly re-allocated to placebo or esketamine. Analysis of the two treatment periods combined showed that the mean difference in change from baseline to day 8 in the total score on the Montgomery-Åsberg Depression Rating Scale compared with placebo was −4·2 (SE 2·09) in the 28 mg esketamine group (p=0·02), −6·3 (2·07) in the 56 mg group (p=0·001), and −9·0 (2·13) in the 84 mg group (p<0·001).

中文翻译：

---

研究综述

在他们的2期临床试验中，Daly及其同事评估了鼻内补充艾草胺在治疗难治性抑郁症中的作用。最初将参与者（n = 67）随机每周两次分配给安慰剂或艾草胺（28 mg，56 mg或84 mg）。在研究的第二周，将具有中度至重度症状的安慰剂参与者随机分配给安慰剂或艾司他明。对这两个治疗期的合并分析表明，与安慰剂相比，蒙哥马利-埃斯伯格抑郁量表的总分从基线到第8天的平均差异为-4·2（SE 2·09）。组（p = 0·02），56 mg组（p = 0·001）-6·3（2·07）和84 mg组-9·0（2·13）（p <0 ·001）。